NEW YORK, Jan. 10, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Agile Therapeutics, Inc. (“Agile Therapeutics”) (NASDAQ:AGRX) between March 9, 2016 and January 3, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/agile-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Agile Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (a) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (b) over half of patients in its “Secure” Phase 3 Study discontinued the study early; and (c) the Twirla patch therefore allegedly had a slight chance of gaining approval by the U.S. Food and Drug Administration.
On January 3, 2017, Agile Therapeutics reported “positive top-line results” for the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. In addition, more than 51% of subjects opted to discontinue the study. Upon this news, shares of Agile Therapeutics fell from a close of $5.70 per share on December 30, 2016, to a close of $2.63 per share on January 4, 2017.
If you suffered a loss in Agile Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Apple Turns 50: From Garage Startup to AI Crossroads
First Western Ship Transits Strait of Hormuz Since Iran War Began
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 



